Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Involvement of CYP2J2 and CYP4F12 in the Metabolism of Ebastine in Human Intestinal Microsomes

Takanori Hashizume, Susumu Imaoka, Masashi Mise, Yoshiaki Terauchi, Toshihiko Fujii, Hisashi Miyazaki, Tetsuya Kamataki and Yoshihiko Funae
Journal of Pharmacology and Experimental Therapeutics January 2002, 300 (1) 298-304; DOI: https://doi.org/10.1124/jpet.300.1.298
Takanori Hashizume
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susumu Imaoka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masashi Mise
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshiaki Terauchi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toshihiko Fujii
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hisashi Miyazaki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tetsuya Kamataki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshihiko Funae
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The purpose of the study was to elucidate human intestinal cytochrome P450 isoform(s) involved in the metabolism of an antihistamine, ebastine, having two major pathways of hydroxylation andN-dealkylation. The ebastine dealkylase in human intestinal microsomes was CYP3A4, based on the inhibition studies with antibodies against CYP1A, CYP2A, CYP2C, CYP2D, CYP2E, and CYP3A isoforms and their selective inhibitors. However, ebastine hydroxylase could not be identified. We then examined the inhibitory effects of anti-CYP4F antibody and 17-octadecynoic acid, an inhibitor of the CYP4 family, on ebastine hydroxylation in intestinal microsomes, since CYP4F was recently found to be the predominant ebastine hydroxylase in monkey intestine; and a novel CYP4F isoform (CYP4F12), also capable of hydroxylating ebastine, was found to exist in human intestine. However, the inhibitory effects were only partial (about 20%) and thus it was thought that, although human CYP4F was involved in ebastine hydroxylation, another predominant enzyme exists. Further screening showed that the hydroxylation was inhibited by arachidonic acid. CYP2J2 was selected as a candidate expressed in the intestine and closely related to arachidonic acid metabolism. The catalytic activity of recombinant CYP2J2 was much higher than that of CYP4F12. Anti-CYP2J antibody inhibited the hydroxylation to about 70% in human intestinal microsomes. These results demonstrate that CYP2J2 is the predominant ebastine hydroxylase in human intestinal microsomes. Thus, the present paper for the first time indicates that, in human intestinal microsomes, both CYP2J and CYP4F subfamilies not only metabolize endogenous substrates but also are involved in the drug metabolism.

  • Abbreviations

    P450
    cytochrome P450
    17-ODYA
    17-octadecynoic acid
    HPLC
    high-performance liquid chromatography
    • Received July 13, 2001.
    • Accepted October 5, 2001.
    • The American Society for Pharmacology and Experimental Therapeutics
    View Full Text

    JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

    Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

     

    • Click here for information on institutional subscriptions.
    • Click here for information on individual ASPET membership.

     

    Log in using your username and password

    Forgot your user name or password?

    Purchase access

    You may purchase access to this article. This will require you to create an account if you don't already have one.
    PreviousNext
    Back to top

    In this issue

    Journal of Pharmacology and Experimental Therapeutics: 300 (1)
    Journal of Pharmacology and Experimental Therapeutics
    Vol. 300, Issue 1
    1 Jan 2002
    • Table of Contents
    • About the Cover
    • Index by author
    Download PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

    NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

    Enter multiple addresses on separate lines or separate them with commas.
    Involvement of CYP2J2 and CYP4F12 in the Metabolism of Ebastine in Human Intestinal Microsomes
    (Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
    (Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    Research ArticleABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

    Involvement of CYP2J2 and CYP4F12 in the Metabolism of Ebastine in Human Intestinal Microsomes

    Takanori Hashizume, Susumu Imaoka, Masashi Mise, Yoshiaki Terauchi, Toshihiko Fujii, Hisashi Miyazaki, Tetsuya Kamataki and Yoshihiko Funae
    Journal of Pharmacology and Experimental Therapeutics January 1, 2002, 300 (1) 298-304; DOI: https://doi.org/10.1124/jpet.300.1.298

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    Research ArticleABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

    Involvement of CYP2J2 and CYP4F12 in the Metabolism of Ebastine in Human Intestinal Microsomes

    Takanori Hashizume, Susumu Imaoka, Masashi Mise, Yoshiaki Terauchi, Toshihiko Fujii, Hisashi Miyazaki, Tetsuya Kamataki and Yoshihiko Funae
    Journal of Pharmacology and Experimental Therapeutics January 1, 2002, 300 (1) 298-304; DOI: https://doi.org/10.1124/jpet.300.1.298
    del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Jump to section

    • Article
      • Abstract
      • Experimental Procedures
      • Results
      • Discussion
      • Acknowledgments
      • Abbreviations
      • References
    • Figures & Data
    • Info & Metrics
    • eLetters
    • PDF

    Related Articles

    Cited By...

    More in this TOC Section

    • Transport Is Not Rate-Limiting in Morphine Glucuronidation in the Single-Pass Perfused Rat Liver Preparation
    • Enhanced Hepatic Uptake and Bioactivity of Type α1(I) Collagen Gene Promoter-Specific Triplex-Forming Oligonucleotides after Conjugation with Cholesterol
    • Characterization of P-glycoprotein Inhibition by Major Cannabinoids from Marijuana
    Show more ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

    Similar Articles

    Advertisement
    • Home
    • Alerts
    Facebook   Twitter   LinkedIn   RSS

    Navigate

    • Current Issue
    • Fast Forward by date
    • Fast Forward by section
    • Latest Articles
    • Archive
    • Search for Articles
    • Feedback
    • ASPET

    More Information

    • About JPET
    • Editorial Board
    • Instructions to Authors
    • Submit a Manuscript
    • Customized Alerts
    • RSS Feeds
    • Subscriptions
    • Permissions
    • Terms & Conditions of Use

    ASPET's Other Journals

    • Drug Metabolism and Disposition
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    ISSN 1521-0103 (Online)

    Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics